Will ARS Pharmaceuticals Be Pratik Shah’s Third Major Success
(Photo: Pratik Shah, chairperson ARS Pharmaceuticals)
August 31, 2024
Last week regulators in the European Union approved the use of an epinephrine nasal spray to treat severe allergic reactions, including those caused by food, medications, and insect bites. Earlier this month, the Food and Drug Administration approved use of the spray – called neffy in the United States - for adults and children, who weigh more than 30 kg (66 lbs.)
The spray is the first and only needle-free delivery of epinephrine for patients living with severe allergic reactions. It is made by San Diego, California, based ARS Pharmaceuticals which is “dedicated to the development of products to better protect patients from severe allergic reactions that could lead to (life-threatening) anaphylaxis.”
The nasal spray is “a treatment alternative that avoids the need to inject epinephrine with a needle, which can be fraught with anxiety and fear for many,” Richard Lowenthal, Co-Founder and Chief Executive of ARS said in a statement. “Epinephrine treatment is only effective if available, readily usable, and administered appropriately.”
CLICK HERE AND ACCESS FULL STORY ON SUBSTACK
FOR FREE WEEKLY GLOBAL INDIAN TIMES STORIES SUBSCRIBE VIA THIS SUBSTACK LINK
(c) All rights reserved. Copyright under United States Laws.
